All In Biotech

Drug Trial Radar · NCT02573350

A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683

A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID With Optional Titration to 200 mg BID for up to Six Months Exposure in Patients With Pulmonary Multi-drug Resistant Tuberculosis

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Mar 26, 2009

Primary completion

Oct 27, 2011

Study completion Oct 27, 2011

Sponsor

Sponsor type
Industry
First posted
Oct 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible. The trial was performed globally at 14 sites qualified to treat MDR-TB. All 434 participants who completed Trial 242-07-204 were eligible for this trial if there was still potential clinical benefit to them and all inclusion criteria and no exclusion criteria were met.

Conditions

  • Tuberculosis, Multidrug-Resistant

Interventions

  • DelamanidDrug

    Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.

  • OBRDrug

    Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinically Significant Abnormality in Vital SignsTime frame: From first dose of study drug up to Week 26
  2. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) ValuesTime frame: From first dose of study drug up to Week 26
  3. Number of Participants With Clinical Significant Abnormality in Laboratory TestTime frame: From first dose of study drug up to Week 26
  4. Number of Participants With Abnormality in Audiometry at BaselineTime frame: Baseline
  5. Number of Participants With Abnormality in Visual AcuityTime frame: From first dose of study drug up to Week 26
  6. Number of Participants With Abnormality in Neurological and Psychiatric Assessment Reported as Treatment-emergent Adverse Event (TEAE)Time frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
  7. Number of Participants With Clinical Significant Abnormality in Thyroid Function Test Reported as TEAETime frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
  8. Number of Participants With Any Concomitant Medication UsageTime frame: From first dose of study drug up to Week 26
  9. Percentage of Participants With At Least One TEAEs and Serious Adverse Events (SAEs)Time frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
  10. Number of Participants With Clinical Significant Abnormality in Coagulation (PT and aPTT) Reported as TEAETime frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
  11. Number of Participants With Clinical Significant Abnormality in CortisolTime frame: From first dose of study drug up to Week 26

Locations

8 sites in 6 countries. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, China

  • North Estonian Medical Centre Foundation Center of Pulmonology

    Tallinn, Estonia

  • Tartu University Lung Hospital

    Tartu, Estonia

  • State Agency of Tuberculosis and Lung Disease

    Riga, Latvia

  • Hospital Nacional Sergio E. Bernales

    Lima, Peru

  • Tropical Disease Foundation

    Makati City, Philippines

  • Younsei University Medical Center

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.